Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
Saved in:
| Title: | Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. |
|---|---|
| Authors: | Hincelin-Mery A; Sanofi, Chilly-Mazarin, France., Nicolas X; Sanofi, Montpellier, France., Cantalloube C; Sanofi, Chilly-Mazarin, France., Pomponio R; Sanofi, Cambridge, Massachusetts, USA., Lewanczyk P; Ividata Life Sciences, Levallois-Perret, France., Benamor M; Sanofi, Chilly-Mazarin, France., Ofengeim D; Sanofi, Cambridge, Massachusetts, USA., Krupka E; Sanofi, Montpellier, France., Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, California, USA., Eastenson A; Nucleus Network Pty Ltd., St. Paul, Minnesota, USA., Atassi N; Sanofi, Cambridge, Massachusetts, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13690. Date of Electronic Publication: 2023 Dec 11. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
